KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Chemistry / 2005 / Cilt: 29 - Sayı: 2

Synthesis and Antimicrobial Evaluation of Some New 2-(2-(p-chlorophenyl) benzimidazol-1-yl methyl)-5-substituted amino-[1,3,4]-thiadiazoles

Gülgün AYHAN KILCIGİL
Canan KUŞ
Sayfa
153–162
Yayın Tarihi
2005-02-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Single crystal X-ray diffraction analysis was performed for compound 8b.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Some 2-(2-(p-chlorophenyl)benzimidazol-1-ylmethyl)-5-substituted amino-[1,3,4]-thiadiazoles were synthesized and their in vitro antimicrobial activities were tested against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Candida krusei.
📊
Temel Bulgular & Veri:Compounds 1b and 12b which possess remarkable activity against C. albicans and marginal activity against C. krusei were found to be the most active compounds in this series.
💡
Sonuç & Katkı:Single crystal X-ray diffraction analysis was performed for compound 8b.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Benzimidazoles · thiadiazoles · antimicrobial activity

Özet

Some 2-(2-(p-chlorophenyl)benzimidazol-1-ylmethyl)-5-substituted amino-[1,3,4]-thiadiazoles were synthesized and their in vitro antimicrobial activities were tested against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Candida krusei. Compounds 1b and 12b which possess remarkable activity against C. albicans and marginal activity against C. krusei were found to be the most active compounds in this series. Single crystal X-ray diffraction analysis was performed for compound 8b.

Abstract

Some 2-(2-(p-chlorophenyl)benzimidazol-1-ylmethyl)-5-substituted amino-[1,3,4]-thiadiazoles were synthesized and their in vitro antimicrobial activities were tested against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Candida krusei. Compounds 1b and 12b which possess remarkable activity against C. albicans and marginal activity against C. krusei were found to be the most active compounds in this series. Single crystal X-ray diffraction analysis was performed for compound 8b.

🔖

Bu Makaleye Atıf Yap

KILCIGİL, G. A., KUŞ, C. (2005). Synthesis and Antimicrobial Evaluation of Some New 2-(2-(p-chlorophenyl) benzimidazol-1-yl methyl)-5-substituted amino-[1,3,4]-thiadiazoles. Turkish Journal of Chemistry, Cilt: 29 - Sayı: 2, 153–162. https://ajindex.com/articles/382202

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (23)

  1. A.E. Abdel-Rahman, A.M. Mahmoud, G.M. El-Naggar and H.A. El-Sherief, Pharmazie, 38, 589-590 (1983).
  2. F.S.G. Soliman, S.M. Rida, E.A.M. Badawey and T. Kappe, Arch. Pharm., 317, 951-958 (1984).
  3. R.A. Coburn, M.T. Clark, R.T. Evans and R.J. Genco, J. Med. Chem., 30, 205-208 (1987).
  4. N.S. Habib, S. Abdel-Hamid, M and El-Hawash, Farmaco, 44, 1225-1232 (1989). H. G¨oker, M. Tun¸cbilek, G. Ayhan and N. Altanlar, Farmaco, 53, 415-420 (1998).
  5. G.A. Kılcıgil, M. Tun¸cbilek, N. Altanlar and H. G¨oker, Farmaco, 54, 562-565 (1999).
  6. V.L. Khairnar, S.R. Lockhande, M.R. Patel and B.G. Khadse, Bull. Haffkine Inst. 8 (1980) 67-70: Chemical Abstract, 95, 203833h (1981).
  7. L.I. Kruse, D.L. Ladd, P.B. Harrsch, F.L. McCabe, S.M. Mong, L. Faucette and R. Johnson, J. Med. Chem., 32, 409-417(1989).
  8. I. Islam, E.B. Skibo, R.T. Dorr and D.S. Alberts, J. Med. Chem., 34, 2954-2961 (1991).
  9. V.J. Habernickel, Drugs made in Germany, 35, 97 (1992).
  10. T. Fukuda, Y. Morimoto, R. Iemura, T. Kawashima, G. Tsukamoto and K. Ito, Arzneim.-Forsch./Drug Res., 34, 801-805 (1984).
  11. T. Fukuda, T. Saito, S. Tajima, K. Shimohara and K. Ito, Arzneim.-Forsch./Drug Res., 34, 805-810 (1984).
  12. H. Nakano, T. Inoue, N. Kawasaki, H. Miyataka, H. Matsumoto, T. Taguchi, N. Inagaki, H. Nagai and T. Satoh, Chem. Pharm. Bull., 47, 1573-1578 (1999).
  13. H. Nakano, T. Inoue, N. Kawasaki, H. Miyataka, H. Matsumoto, T. Taguchi, N. Inagaki, H. Nagai and T. Satoh, Bioorg. Med. Chem., 8, 373-380 (2000).
  14. B. Can-Eke, M.O. Puskullu, E. Buyukbingol and M. Iscan, Chemico-Biological Interactions, 113, 65-77 (1998).
  15. S. Demirayak, U. Abu Mohsen and A.C. Karaburun, Eur. J. Med. Chem., 37, 255-260 (2002).
  16. S. Ersan, S. Nacak, N. Noyanalpan and E. Yesilada, Arzneim.-Forsch./Drug Res., 47, 834-836 (1997).
  17. D.H. Boschelli, D.T. Connor, D.A. Bornemeier, R.D. Dyer, J.A. Kennedy, P.J. Kuipers, G.C. Okonkwo, D.J. Schrier and C.D. Wright, J. Med. Chem., 36, 1802-1810 (1993).
  18. G. Sahin, E. Palaska, P. Kelicen, R. Demirdamar and G. Altınok, Arzneim.-Forsch./Drug Res., 51, 478-484 (2001).
  19. A. Tsotinis, A. Varvaresou, T. Calogeropoulou, T. Siatra-Papastaikoudi and A. Tiligada, Arzneim.-Forsch./Drug Res., 47, 307-310 (1997).
  20. A.C.T. North, D.C. Phillips and F.S. Mathews, Acta Cryst., A24, 351-359 (1968).
  21. G.M. Sheldrick, SHELXS97 Program for Crystal Structure Solution, University of G¨ottingen, Germany (1997).
  22. G.M. Sheldrick, SHELXL97 Program for Crystal Structure Refinement, University of G¨ottingen, Germany (1997).
  23. D.F. Sahm, J.A. Washington in Am. Soc. Microbiol.